"Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.

Alessandro Padovani, Salvatore Caratozzolo, Luca Rozzini, Andrea Pilotto, Alberto Benussi, Gioacchino Tedeschi

Journal: Journal of the American Geriatrics Society 2022;70(2):626-628

PMID: 34750815

Free Full Text on PubMed Central View on PubMed

Abstract

See related editorial by Lundebjerg et al.

Address: Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.; Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, Brescia, Italy.; Neurology Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

DOI: 10.1111/jgs.17530

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/alzheimersdisease.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Aged, Alzheimer Disease, Antibodies, Monoclonal, Humanized, Cognitive Dysfunction, Disease Progression, Drug Approval, Eligibility Determination, Humans, United States, United States Food and Drug Administration